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ABSTRACT 
Atherosclerosis is the underlying pathology of many cardiovascular diseases. The formation 
and rupture of atherosclerotic plaques in the coronary arteries results in angina and 
myocardial infarction. Venous coronary artery bypass grafts (CABG) are designed to reduce 
the symptoms of atherosclerosis in the coronary arteries by diverting blood flow around the 
atherosclerotic plaques. However, vein grafts suffer a high failure rate due to intimal 
thickening that occurs as a result of vascular cell injury and activation and can act as ‘a soil’ 
for subsequent atherosclerotic plaque formation. A clinically-proven method for the 
reduction of vein graft intimal thickening and subsequent major adverse clinical events is 
currently not available. Consequently, a greater understanding of the underlying mechanisms 
of intimal thickening may be beneficial for the design of future therapies for vein graft failure. 
Vein grafting induces inflammation and endothelial cell damage and dysfunction, that 
promotes vascular smooth muscle cell (VSMC) migration and proliferation. Injury to the wall 
of the vein as a result of grafting leads to the production of chemoattractants, remodelling of 
the extracellular matrix and cell-cell contacts; which all contribute to the induction of VSMC 
migration and proliferation. This review focuses on the role of altered behaviour of VSMCs in 
the vein graft and some of the factors which critically lead to intimal thickening that 
predisposes the vein graft to further atherosclerosis and reoccurrence of symptoms in the 
patient. 
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SAPHENOUS VEIN GRAFTING 
Atherosclerosis is the underlying pathology in many cardiovascular diseases. Coronary artery 
bypass graft (CABG) surgery is the most frequently performed surgical intervention for 
relieving symptoms associated with ruptured or occlusive coronary artery atherosclerotic 
plaques 1, 2. Surgery entails usage of non-native, un-diseased vessel (most often the 
saphenous vein, internal mammary artery or radial artery) for diversion of blood from the 
aorta to the coronary artery, distal to the stenosed region, thereby re-vascularising cardiac 
tissue. Despite improvements in surgical techniques and medical management, long-term 
efficacy of bypass grafts, especially saphenous vein grafts, remains restricted due to complete 
or significant occlusion (restenosis) of the conduits or continued progression of 
atherosclerosis in native coronary arteries 3. Though arterial grafts exhibit superior patency 
rates to saphenous vein grafts 4-10, the latter is most commonly used as it is easier to harvest 
and manipulate, and its length allows for reaching of any coronary artery and making of 
multiple grafts 11. However, the prognosis is such that 10-15% of saphenous vein grafts are 
predisposed to early failure within the first year of surgery, and up to 50% suffer late vein 
graft failure within 10 years 1, 2, 6. Numerous studies have attempted to identify treatments 
for effectively ameliorating late vein graft stenosis though no validated interventional 
strategies currently exist. Advances in our understanding of the epidemiology and aetiology 
of saphenous vein graft failure are thus essential for the design of preventative therapies.  
 
PATHOGENESIS OF SAPHENOUS VEIN GRAFT FAILURE 
Thrombosis, intimal hyperplasia and accelerated atherosclerosis are the primary 
pathophysiological events underlying saphenous vein graft failure (Figure 1) 12. Thrombosis 
typically occurs within one month of surgery in 3-15% of patients 13, 14 and is a direct 
consequence of endothelial dysfunction 12. Disruption to the endothelium is in turn a product 
of high pressure distension used to overcome vasospasm during surgery and to disrupt the 
venous valves 15, and tissue handling during harvesting and implantation of the vein conduit 
16. Focal endothelial loss is most prominent at the sites of anastomosis 3. After implantation 
the vein graft is subjected to considerably altered blood flow and wall stress than from its 
original source of the venous system. This is also thought to contribute to endothelial cell 
damage and loss from the luminal surface 17. Loss of the endothelial monolayer and 
endothelial dysfunction induce adherence and accumulation of fibrin, platelets and 
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neutrophils to the luminal surface of the vessel wall 18, 19 and causes an attenuation in 
production of thrombolytic agents, including tissue plasminogen activator (tPA) 20, and 
thrombomodulin – a protein cofactor normally expressed on the surface of endothelial cells 
that complexes with thrombin to activate protein C, a potent anticoagulant 21. Furthermore, 
the inherent antithrombotic properties of veins are comparatively weak with respect to 
arteries; for example, expression of anticoagulant heparin sulphate, and production of 
platelet activation inhibitors including nitric oxide (NO) and prostacyclin, is notably reduced 
in veins with respect to arteries 12, 17. The propensity for thrombus formation is also amplified 
by such factors as intact venous valves, vein distension, reduced flow and anastomotic error 
3. Thus, even when saphenous vein graft surgeries are performed optimally, there remains an 
inherent predisposition for generation of thrombi. Further endothelial damage and 
dysfunction is caused after Implantation into the arterial circulation, this is discussed in more 
detail later in this review. 
 
Intimal hyperplasia is a consequence of VSMC accumulation and their deposition of 
extracellular matrix (ECM) (Figure 1). Most veins display fibrosis of the intimal or medial 
compartments prior to grafting 22, though further postoperative intimal thickening can 
impinge on the lumen by up to 25% within the first 4-6 weeks following surgery 12. Though 
rarely enough to induce significant stenosis alone 23, intimal hyperplasia serves as a 
foundation for accelerated, superimposed atherosclerosis 24. Intimal fibrosis, in part, 
precipitates from transient ischemia within the graft. Hypoxia has been detected in the vein 
graft and it has been proposed that chronic exposure in contrast to transient hypoxia 
promotes intimal thickening in grafts. In response to hypoxia there is a marked induction of 
superoxide radical formation in the vessel wall and an attenuation in endothelial cell 
production of anti-mitotic agents including prostacyclin, NO, and adenosine directly 
promoting intimal VSMC migration and replication 25, 26. In addition, re-endothelialisation 
over non-occlusive thrombi – platelet and fibrin deposits at the luminal surface – allows for 
progressive organisation of the thrombi into fibrotic tissue; subsequently, platelets release 
various growth factors and cytokines compounding VSMC proliferation and thereby intimal 
thickening 19. Such mitogens are also secreted by endothelial cells, macrophages and VSMCs 
themselves 17, 18, 27. Neointima formation is further exacerbated by increased wall stress and 
distension of the vein graft when subjected to pulsatile pressures of the arterial system 3, 12. 
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This is described in more detail later in this review. Elevated tangential stress promotes 
production of mitogenic agents including platelet-derived growth factor (PDGF), basic 
fibroblast growth factor (bFGF) and endothelin 1, and inhibits synthesis of anti-proliferative 
factors such as transforming growth factor- (TGF-β) and NO 17, 27, 28. All these elements 
combined confer on saphenous vein grafts a high susceptibility to generation of restenotic 
lesions.  
 
The focus of this review is the role of altered behaviour of VSMCs within the vein graft. This 
is due to both inherent differences in the composition of the vein and divergent behaviour of 
venous VSMCs (v-VSMCs) and arterial VSMCs (A-VSMCs), see Figures 2 and 3. Within the 
native vein and artery in their natural environment the VSMCs predominantly exist in a 
quiescent phenotype. The main function of the VSMC is contraction and thereby regulation 
of blood flow and pressure. VSMCs are not terminally differentiated and can switch from the 
quiescent contractile differentiated phenotype to a de-differentiated synthetic phenotype 33. 
In veins there is a higher incidence of de-differentiated VSMCs than arteries. This switch 
occurs in response to a number of stimuli including hypoxia, endothelial dysfunction and 
inflammation 33 and is also induced prior to grafting by surgical preparation of the vein 34. De-
differentiation involves VSMCs loss if contractile proteins such as -smooth muscle actin, 
myosin heavy chain and smoothelin, and enhanced extracellular matrix and inflammatory 
cytokines production 35. This phenotypic transformation observed in grafts at 1 month plays 
a major pathophysiologic role in intimal thickening. 
 
Though the widely accepted rationale for development of neointimal hyperplasia is that 
mature, quiescent medial VSMCs de-differentiate into proliferative and synthetic VSMCs 29-
31, over the past decade, an array of studies have identified alternative vascular progenitors 
that may contribute to the overall neointimal VSMC population. Controversy still remains 
over the origin of the intimal vein graft cells in vein graft. It is considered by some that intimal 
cells are exclusively from the vein graft 37. Others proposed that bone marrow or “graft-
extrinsic” cells are the major source of intimal cells 38. A more recent study by Liang et al 
showed that ~54 % of SMA-α-positive cells in the neointima of mouse vein grafts originated 
from the flanking recipient artery 39. Interestingly bone marrow cells did not contribute to the 
SMCs of the neointima in vein grafts. This is consistent with a previous study in which all graft 
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cells migrated from the flanking artery without any contribution from putative progenitor 
cells in the blood in arterial allografts in mice 40. Not all the host-derived cells expressed the 
SMC marker a-smooth muscle actin (~10% were negative), which may represent the de-
differentiated VSMCs. It is also of note that some of the neointimal VSMCs within the vein 
graft were from other sources, possibly SMC progenitors 41, 42, endothelial cells 41, 43, or 
adventitial cells 44, 45. Using nanofibrous vascular grafts interposition into the carotid artery of 
athymic rats Tang et al demonstrated that multipotent vascular stem cells (MVSC) 
differentiated into mature VSMCs 46. However, Liang et al concluded that de-differentiation 
of SMCs in the anastomosed arteries are the major contributor to intimal thickening 39. 
Additional strategies are required to further examine the contribution of MVSCs to intimal 
thickening, such as a tamoxifen-inducible SMC-Cre reporter and/or SOX10-Cre reporter mice. 
Whether alternative vascular progenitors play a salient role in the generation of proliferative 
and synthetic VSMCs in human grafts remains unclear and subject to debate and is most likely 
dependent on the degree of injury to the graft either during or following the procedure as 
this influences the release of factors that induce homing of stem cells to the site of injury. To 
date fate tracing experiments have not been performed in a suitable large animal model of 
vein grafting to determine directly whether neointimal cells are derived from mature VSMCs 
or from progenitor cells. Notwithstanding the involvement of progenitor cells, it is still 
presumed that mature, quiescent medial VSMCs, at least to an extent, participate in intimal 
thickening and formation of occlusive lesions.  
 
Beyond the first year following CABG surgery, atherosclerosis is the dominant 
pathophysiological process responsible for restenosis and saphenous vein graft degeneration 
(Figure 1) 12, 47, 48. Atheroma development in vein grafts is similar to that in native arteries, 
though there are a few temporal, histological and topographical discrepancies 12. Firstly, the 
progression of atherosclerosis is more rapid in saphenous vein grafts compared to native 
coronary arteries as chronic endothelial dysfunction 19, 49 and pronounced intimal fibrosis 24 
observed in the former generate a highly atherogenic environment. Secondly, diseased vein 
grafts accommodate more inflammatory cells, including foam cell macrophages and 
multinucleate giant cells 50, and display higher rates of lipid-uptake and lipid synthesis, than 
native coronary arteries 51. Lastly, morphologically, coronary artery vein graft atheromas are 
diffuse, concentric (Figure 1) and show poorly developed or absent fibrous caps and little 
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evidence of calcification, whereas native coronary atheromas are focal, eccentric and exhibit 
well-developed fibrous caps and calcification 50, 52-54. However, as with native atheromas, 
restenotic and atherosclerotic lesions within grafts are prone to rupture, resulting in the 
reoccurrence of ischemic myocardial injury 55; thus, study of the molecular dynamics 
underlying this pathology is essential for the design of new and improved treatments.  
 
FACTORS INVOLVED IN ACTIVATION OF V-VSMCS 
In this review we have focussed on the role of the VSMC in the formation of intimal thickening 
which predisposes the graft to atherosclerosis. There are a number of inherent differences in 
the composition and cells of the vein and the host artery which may affect the behaviour of 
the graft cells and thereby contribute to intimal thickening (summarised in Figures 2 and 3).  
 
COMPOSITION OF VEIN GRAFT 
It has been clearly demonstrated that the composition of saphenous vein and internal 
mammary artery differs considerably and this may also contribute to the divergent graft 
patency rates 56. For example, in comparison to internal mammary artery, saphenous vein has 
high levels of dermatan sulphate, collagen and salusin-while low levels of heparin sulphate, 
esterified and free cholesterol, phospholipids, DNA, protein, total glycosaminoglycans, 
hyaluronic acid, chondroitin sulphate, nitric oxide (NO), salusin- and apelin-36. 
Approximately 65% of the saphenous vein is collagen whilst lower amounts are present in the 
internal mammary artery 57. Furthermore, the internal mammary has higher medial elastic 
lamina than the saphenous vein, providing greater elasticity, and reducing deformation and 
compliance. Intimal thickening is caused by VSMCs migrating through the internal elastica 
lamina and invading the intima. Therefore, the internal elastic lamina as a barrier to smooth 
muscle cells 58. In addition, this difference in ECM composition and cellularity results in a 
compliance mis-match between the stiffer vein graft and the artery, this is further 
exaggerated at the anastomosis 59. The saphenous vein contains less heparan sulphate than 
the internal mammary artery due to reduced cellularity 57. Contrastingly, there is augmented 
dermatan sulphate in glycosaminoglycans in the saphenous vein than the internal mammary 
artery, which provides enhanced affinity for LDL and VLDL than other glycosaminoglycans 
components. This may explain in part why the saphenous vein graft has an enhanced 
propensity to atherosclerosis. 
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Divergent secretion of soluble factors may also favour intimal thickening in the vein graft. 
Saphenous vein secretes less NO 60, a vasodilator which inhibits thrombosis and is critical for 
lumen patency 61, and therefore this is thought to contribute to enhanced intimal thickening 
and reduced graft patency. Reduced sensitivity of the saphenous vein to vasoactive materials 
may also contribute to a low patency rate 57. Moreover, A-ECs secret higher levels of 
endothelium-dependent relaxation factor (EDRF) than veins which also protects against 
intravascular thrombus formation. Moreover, GSV secretes less NO 60. Veins also secrete 
different types and amounts of vasodilatory substances 56. Lower amounts of the peptides 
apelin and salusin in the saphenous vein than arteries and could influence the vasodilatory 
properties of the graft and thereby patency. 
 
DIFFERENCES IN VASCULAR CELLS 
In addition, to differences in composition inherent differences in the grafted vascular cells 
with the host vascular cells may contribute to intimal thickening. A number of studies have 
demonstrated contrasting properties of arterial VSMCs (A-VSMCs) and venous VSMCs (V-
VSMCs). The distinct properties of V-VSMCs may contribute to the intimal thickening and late 
failure of venous grafts. As hypoxia occurs at the anastomosis of synthetic grafts 62 and 
arteriovenous fistulas 63, it is of relevant to determine the effect of hypoxia on VSMC 
behaviour. VSMC migration and proliferation was enhanced in venous VSMCs compared to 
arterial VSMCs 64 65. Interestingly the mechanism of induction also differed, with V-VSMCs 
utilising vascular endothelial growth factor (VEGF)-A via VEGF-receptor-1 whilst arterial 
hypoxia-induced migration and proliferation was predominantly mediated by PDGF-BB 64, 65. 
It is therefore likely that differential regulation of VSMC migration and proliferation under 
hypoxia contributes to the differences in intimal thickening observed in vein and arterial 
grafts despite hypoxia occurring in both types of graft. It should be noted however that a 
limitation of these studies is the use of umbilical cord cells and future studies utilising 
saphenous vein to compare with arterial graft VSMCs and native coronary artery VSMCs 
would be beneficial. It has also been proposed that the augmented proliferative responses V-
VSMCs to hypoxia compared to A-VSMCs are due to the differential responses of SMC 
proliferation to hypoxic EC-derived growth factors such as PDGF-AB 66. Moreover V-VSMCs 
express higher levels of PDGF-Rβ expression and exhibit transactivation of epidermal growth 
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factor (EGF)-receptor by PDGF-BB. Contrastingly, A-VSMCs, but not V-VSMCs, induce 
proliferation in response to PDGF-AA, presumably via activation of the PDGF-
Rα/JNK1/p27kip1 pathway 67. 
 
V-VSMCs exhibit a more de-differentiated phenotype to A-VSMCs, exhibiting heightened 
proliferative and synthetic capacity 68. In culture it is apparent that V-VSMCs are smaller, more 
spindle-shaped, and demonstrate higher proliferative and migratory rates than A-VSMCs. 
Moreover, increased SMemb expression and decreased α-actin is indicative of a more 
dedifferentiated phenotype in V-VSMCs, as well as enhanced expression of MMP-2 and MMP-
9. Additionally, adhesion to both collagen and fibronectin was significantly lower for V-VSMCs 
than A-VSMCs. Notably, the expression of decorin was significantly higher in A-VSMCs than 
V-VSMCs and this may contribute to their altered behaviour 68. Consequently, strategies to 
enhance decorin expression may be beneficial for retarding vein graft intimal thickening. A 
limitation of this study is the use of cultured cells and isolation of carotid arteries and jugular 
veins from rabbits. Future studies are required using human VSMCs from saphenous vein and 
coronary artery to demonstrate the generality of these findings.  
 
Observed differences in the behaviour of VSMC derived from saphenous vein to A-VSMCs 
could facilitate development of new pharmacotherapy, directed specifically at venous intimal 
hyperplasia. Such therapeutic strategies could be formulated to the type of vessel graft and 
could prevent restenosis in saphenous vein grafts 67.  
 
Differences in arterial and venous cells may not be restricted to VSMCs, and differences in 
arterial endothelial cells (A-ECs) and venous endothelial cells (V-ECs) may have important 
ramifications on vein graft failure. Short-term exposure of V-ECs to high shear stress such as 
that encountered in the venous graft after implantation into arterial circulation the leads to 
proinflammatory activation of the ECs by the induction of MAP kinase phosphatase-1 69. 
Interestingly, this does not occur in A-ECs. Dexamethasone pre-treatment of the V-ECs, 
‘arterializes’ them by inducing MAP kinase phosphatase-1 and it is therefore possible that this 
approach may protect veins from inflammation. The observed differences in response of V-
ECs and A-ECs may reflect epigenetic memory of the markedly different hemodynamic 
environments of their origin. The shear stresses in arteries are markedly higher (10 to 20 
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dynes/cm2) than veins (<5 dynes/cm2). Cultured A-ECs may be pre-adapted to the arterial 
environment and retain this resistance in culture, whereas v-ECs are primed by the venous 
environment. There are also non-hemodynamic factors which contribute to the arterial-
venous heterogeneity, including epigenetic modifications and cellular signalling pathways 
that control A-EC and V-EC differentiation in embryonic vessels before circulation of blood 70. 
The altered response to shear stress by the V-ECs may lead to the release of inflammatory 
and pro-proliferative factors that cause activation of the underlying V-VSMCs. 
 
INJURY TO GRAFT 
The endothelium and VSMCs of the vein graft are damaged during the preparation and the 
implantation of the vein graft. The graft is injured in various ways: physical damage by the use 
of instruments used to harvest the vein from the patient’s leg, application of high intra-
luminal pressure to check for leakage and disruption of the valves, deployment of clips or 
sutures to seal side branches. Additionally, damage is caused by implantation into the arterial 
circulation leading to exposure to high arterial blood pressure and flow causing further 
damage to the endothelium 17. The damaged endothelium disrupts the physiological balance 
of the vein and this is further disturbed by release of factors from damaged VSMCs 71. The 
imbalance leads to accelerated VSMC proliferation and is proportional to the degree of injury 
72. This response is considered as a wound healing response that leads to intimal and media 
thickening in an attempt to become arterialised. However, the thickening of the vein graft 
ultimately becomes problematic as the required adaptation to the arterial circulation leads 
to an environment that is susceptible to superimposed atherosclerosis which leads to re-
occurrence of symptoms. It would be highly beneficial if grafts could be monitored for the 
occurrence of arterialisation to determine the point at which detrimental superimposed 
atherosclerosis was initiated and suitable treatments could be applied at this timepoint. 
However, currently this has not been established in a suitable large animal model or in 
humans. 
 
BIOMECHANICAL FACTORS 
Biomechanical factors are a major contributor to the incidence and distribution of bypass 
graft disease 59. Disturbed local haemodynamics are known to be involved in the formation 
of intimal thickening. It has been illustrated that end-to-side graft –artery implantation is 
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responsible for disturbed flow patterns which make the vein susceptible to remodelling in the 
occurrence of intimal thickening 73. Low-wall shear stress and high-wall mechanical stress or 
strain are two major factors 74. Additionally, a range of secondary factors are involved 
including vessel geometry; vessel movement; vessel wall characteristics and the presence of 
reflection waves 75. However, to date no surgical differences have been made to significantly 
reduce intimal thickening by alteration of biomechanical factors. Increasing the awareness of 
the effects of the biomechanical factors on the vein graft may facilitate new approaches to 
reduce the failure rate of coronary artery vein grafts.  
 
It is apparent that flow pattern regulates cell proliferation and migration. Using a venous 
polymer implant in rats, vortex blood flow induced VSMC migration and neointimal 
hyperplasia, whereas the reduced vortex blood flow in the modified vein graft strongly 
suppressed these effects via the phosphorylation of ERK1/2 and myosin light chain kinase 76. 
Elevated cyclic stretch is thought to be one of the major contributors to intimal thickening 
due to the differences in the venous and arterial environment 12. Moreover, mechanical 
stretch in vitro causes a differential effect on VSMCs from different sources. Enhanced 
proliferation is not observed in A-VSMCs after stretching at 0.05 and 1 Hz when compared 
with unstretched controls. By contrast, stretching of V-VSMCs both at 0.05 and 1 Hz result 
significantly augmented proliferation compared with static controls 77, 78, via IGF-1 receptor 
activation and serum-, glucocorticoid-regulated kinase 1 79, 80. Thereby it can be proposed that 
the accelerated V-VSMC proliferation, within vein grafts in vivo, is partially the response of 
the induction of proliferation of V-VSMCs to mechanical stimulation. It is plausible therefor 
that a biomechanical engineering approach with adaptive training of V-VSMCs prior to 
grafting could possibly improve vein graft patency. 
 
Speculatively, movement may have an effect on graft patency. At the junction between the 
stationary aorta and the partially mobile vein graft there may be increased local wall stresses 
and strains as well as the graft being exposed to a repeated torsional or pendular movement 
depending on the site of the anastomosis. Experimental external stents which reduce some 
of the biomechanical forces reduced intimal thickening 81, however this did not translate into 
clinical benefit in humans due to kinking of the graft within the external stent 82. Development 
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of a flexible, biodegradable external stent that can surround both the anastamosis and the 
mid-portion of the graft is essential. 
 
The vein graft is proposed to be subjected to high blood pressure and flow stagnation in 
systole and high flow-induced high shear stress and potentially erosion in diastole. To 
examine this Piola et al established an ex vivo flow model. They observed that although 
pulsatile stimulation did not affect vessel wall integrity and size, it caused partial endothelial 
denudation, apoptosis in the vessel wall, and altered medial and intimal thickness 83. These 
data could mimic the early vessel remodelling events in vein grafts. 
 
As mentioned previously the composition of the ECM and the cellularity (and thereby the 
amount of cell-cell cadherin mediated contacts) of veins differs from that of arteries and may 
contribute to the altered behaviour of VSMCs in grafts by enhancing migration and 
proliferation. Therefore the role of some of the components of the ECM and cadherin 
contacts in the regulation of VSMC behaviour will be discussed in more detail in the following 
sections. 
 
EXTRACELLULAR MATRIX 
ECM synthesis not only serves as marker of the active VSMC phenotype, but many of the 
matrix molecules produced are bioactive and regulate proliferation and migration. 
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Elastin 
Elastin is a stable matrix molecule deposited in vessels during embryonic and early neonatal 
life. It is a hydrophobic protein composed of cross-linked tropoelastin molecules. Intact 
elastin inhibits VSMC proliferation to help maintain vessel quiescence. Elastin-deficient mice 
die early after birth from complete arterial occlusion, which is secondary to robust 
proliferation and migration of VSMCs from the medial into the intimal layer 85. With the 
development of vascular disease, there is significant degradation and disruption of elastin. 
Elastin degradation is mediated by at least three groups of elastases; serine proteases (i.e. 
neutrophil elastase and cathepsin G), cysteine proteases (i.e. cathepsin L, S, K and V) and 
MMPs (i.e. MMP-2, -7, -9, and -12) 86. Elastin degradation results in the accumulation of 
elastin-derived peptides which have been shown to increase VSMC proliferation and 
migration 87. 
 
Type I collagen 
Type I collagen is a triple helical molecule composed of heterotrimers of 1 and 2 chains. In 
intimal hyperplasia type I collagen is found in abundance, and in the context of the injured 
vessel wall it is present in varied states of assembly or degradation each of which can have 
distinct effects upon VSMC migration and proliferation. Like elastin, intact or polymeric type 
I collagen maintains VSMC quiescence, while monomeric or degraded collagen promotes 
VSMC proliferation and migration. Early studies revealed that plating VSMCs on polymerized 
collagen resulted in suppression of growth mediated by cyclin dependent kinase inhibitors 88, 
89 , while treating cells with monomeric or soluble collagen stimulated proliferation 8890 . 
Plating on monomeric collagen also decreased the expression of VSMC differentiation 
markers, and led to the upregulation of the inflammatory adhesion molecule VCAM 91. In vivo 
studies of the response to injury in pig coronary arteries provided support for this notion, 
because accumulation of collagen was correlated with the upregulation of cyclin inhibitors 
and a decrease in VSMC proliferation 92 . Type I collagen also acts via receptor cross-talk 
between integrins and growth factors to potentiate the proliferative signaling induced by 
platelet derived growth factor (PDGF-BB) 93. VSMCs are able to migrate faster across a 
monomeric collagen matrix than a polymerized matrix 88, 94, 95 . In fact, proteolysis of the 
collagen matrix is required for migration in both 2D and 3D gels, not just to degrade matrix 
barriers, but collagen fragments help to break up focal adhesions allowing cell release and 
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translocation 96, 97 . There is also evidence that cell deposit new collagen on top of existing 
matrix to form a provisional matrix more permissive for migration 98, 99 . Treatment of cells to 
inhibit collagen synthesis prevents focal adhesion formation, actin stress fiber assembly, and 
migration irrespective of the initial matrix used to coat the plate 100. The differences in 
response to different physical states of collagen are partially related to the ease with which 
cells can release from the ECM, however there is also clear evidence that different physical 
forms of collagen can trigger activation of distinct signaling pathways. 
 
Type VIII collagen 
It is well established that type VIII collagen expression is dramatically increased in vascular 
injury and disease 101-104. Type VIII collagen is a short chain, network-forming collagen 
composed of two chains, procollagen α1(VIII) and procollagen α2(VIII), which are encoded by 
two separate genes, Col8a1 and Col8a2 106. Type VIII collagen is central to the control of VSMC 
proliferation and migration making important contributions to the development of intimal 
hyperplasia. In vitro studies show that type VIII collagen acts as a chemotactic and haptotactic 
factor for VSMCs 107, 108. VSMCs adhere less strongly to type VIII collagen compared to type I 
collagen, and addition of type VIII collagen to a polymeric type I collagen matrix allows release 
and migration of cells across the matrix, suggesting that type VIII collagen can form a 
provisional matrix 107. VSMCs isolated from collagen VIII deficient mice (Col8-/-) displayed 
reduced migration, proliferation and MMP-2 production compared to cells from wild-type 
mice 109. The Col8-/- cells had prominent actin stress fibers, stable microtubules, and numerous 
basal focal adhesions, all due to enhanced activation of RhoA 110. Addition of exogenous type 
VIII collagen suppressed RhoA, restored MMP-2 activity, and enhanced proliferation and 
migration in these cells 110. These studies show that type VIII collagen regulates cytoskeletal 
configuration and MMP-2 expression to facilitate VSMC migration. In vivo studies confirmed 
the role of type VIII collagen in promoting VSMC proliferation and migration to the neointima. 
Col8-/- mice subject to wire injury of the femoral artery had less VSMC accumulation and less 
wall thickening compared to Col8+/+ mice 111, revealing an important role for type VIII collagen 
in regulating VSMC migration and infiltration into the vessel neointima. Type VIII collagen 
112.expression is mediated by the transcription factor KLF4, which is also a critical factor 
mediating the VSMC phenotypic switch 112 and therefore type VIII collagen expression would 
be increased during VSMC de-differentiation, promoting VSMC migration and proliferation.  
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CELL-CELL CONTACTS - CADHERINS 
The cadherins are a superfamily of transmembrane glycoproteins that mediate homophilic 
cell-cell adhesions 119. Cadherin expression is cell-type specific, and the predominant classical 
cadherin expressed by VSMCs is N-cadherin 120. Extracellular domain 1 (EC1) of the classical 
cadherins contains a HAV binding motif, which interacts with cadherins on adjacent cells in a 
zipper-like fashi. Fibroblast growth factor receptor (FGF-R) also contains an HAV motif, which 
permits the formation of a heterodimer with EC4 within the N-cadherin molecule 121. Whilst 
the extracellular domain of classical cadherins regulates homophilic cell-cell adhesion the 
intracellular domain modulates cell signalling. The most-well characterised signalling pathway 
is the -catenin/Wnt pathway 122. Cytoplasmic accumulation of -catenin facilitates 
movement of -catenin to the nucleus where it binds to T-cell factor (TCF), and resulting in 
up- or down-regulation of downstream genes 123, including those involved in the cell cycle 
(cyclin D1 124 and c-myc 125), and migration (versican 126, fibronectin 127, matrix 
metalloproteinase-7 (MMP-7) 128 and membrane-tethered MMP-1 (MT1-MMP) 129). Cell 
signalling and thereby behaviour is also modulated by cadherins via interaction with Rho 
GTPases 130 and receptor tyrosine kinases, including FGF-R 131. 
 
It has been clearly demonstrated that N-cadherin regulates VSMC proliferation and, 
migration, and that this is mediated at least in part by interaction with the FGF-R (Figure 2) 
120, 121, 132-138. VSMC proliferation is inhibited by N-cadherin, via -catenin signalling 139. N-
cadherin cell-cell contacts are modulated by proteolytic shedding by MMPs including MMP-9 
and -12, but not MMP-2 and -14 136, which frees -catenin permitting it’s movement to the 
nucleus 139, 140. Inhibiting β-catenin signalling reduces proliferation, due to a reduction in the 
expression of β-catenin responsive genes, cyclin D1 and p21, which are involved in cell cycle 
regulation 137. In cells lacking MMPs 9 and 12 there was less  catenin signalling, and 
attenuated cyclin D1 expression, presumably because N-cadherin is maintained and can 
therefore retain  catenin at the membrane rather than releasing it for signalling 136. 
Discrepant findings for the role of N-cadherin in VSMC migration have been reported. In some 
studies it was concluded that N-cadherin was pro-migratory 143, 144. However, in another 
studies N-cadherin inhibited migration of VSMCs 146, 147. 
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Loss of cadherins during proliferation leads to the release of free -catenin which in turn can 
induce Wnt signalling. Indeed it has been demonstrated that Wnt-catenin signalling 
regulates both VSMC migration and proliferation in various studies 137, 160-168, 170, 171. The 
compelling evidence for the involvement of Wnt signalling in VSMC proliferation and thereby 
intimal thickening has led to the suggestion that activation of the Wnt/-catenin pathway is 
a marker of culprit VSMCs that lead to intimal. Consequently, targeting Wnt activated VSMCs 
could reduce intimal thickening. This is supported by the following studies. Firstly, conditional 
smooth muscle specific deletion of-catenin reduced intimal thickening in mice 173. 
Additionally, the Wnt/β-catenin inhibitor XAV939 inhibited intimal thickening in mice 
subjected to carotid artery ligation 174. Two recent studies using the mouse carotid artery 
ligation model demonstrated that selective suicide of cells with active Wnt signalling retards 
intimal thickening 175, 176. 
 
SUMMARY 
In summary, VSMC play a major role in the remodelling of the saphenous vein graft after 
implantation by contributing to the thickening of the intimal. Accelerated intimal thickening 
in the vein graft is the result of a number of inherent divergent properties of the vein and its 
vascular cells and the biomechanical and environment factors after implantation as outlined 
in this review. These result in activation of V-VSMCs and modulation of their behaviour by 
several factors including ECM and cadherin contacts. The thickened intima is highly 
susceptible to superimposed atherosclerosis which leads to reoccurrence of symptoms and 
the need for future treatments. To improve vein graft patency strategies are required to 
reduce the deleterious biomechanical and environmental factors by altering surgical 
procedures or by application of treatments which retard the detrimental remodelling of the 
artery. Identification of the timepoint when beneficial remodelling and arterialisation of the 
vein transfers to superimposed atherosclerosis would be highly advantageous but required 
improved imaging techniques or identification of suitable biomarkers. 
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Figure 1. Early and late vein graft failure.  
Normal vein structure showing the three layers within the vessel wall: intima, media and 
adventitia. Processes involved in early and late vein graft failure. Early vein graft failure is 
driven by thrombosis. Late vein graft failure is driven by intimal thickening and 
superimposed atherosclerosis. Images are from Servier art. 
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Figure 2. Comparison of venous and arterial cells.  
Differences in the properties of venous and arterial cells that alter cell behaviour and may 
contribute to the poor patency of coronary artery vein grafts. Images are from Servier art. 
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Figure 3. Comparison of veins and arteries.  
Structural and compositional differences of veins and arteries that may contribute to the 
poor patency of coronary artery vein grafts. Images are from Servier art. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
